Abstract: Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a therapeutic moiety linked to a half-life extension moiety via a fibroblast activation protein, alpha (FAP?)-cleavable linker. Methods of using the therapeutic conjugates are also provided.

Abstract: Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a drug moiety linked to a half-life extension moiety via an enzyme-cleavable linker. Methods of using the therapeutic conjugates are also provided.

Abstract: Provided herein, in some embodiments, are recombinantly engineered variant of stefin polypeptides (AFFIMER® polypeptides) that binds to human serum albumin and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are composition containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.

Abstract: Provided herein, in some embodiments, are fusion proteins comprising recombinantly engineered variant of stefin polypeptide (an AFFIMER® polypeptide) that binds to PD-L1 and a polypeptide that binds to human serum albumin (HSA). Also provided herein, in some embodiments, are compositions containing the fusion proteins, methods of using the fusion proteins, and methods of producing the fusion proteins.

Abstract: Disclosed are binder-drug conjugates that are activated extracellular, with both the binder and the free drug moiety have pharmacological activity.

Abstract: The present disclosure relates to proteins including PD-L1 binding affimer polypeptide sequences, gene expression constructs encoded those proteins, cells expressing those proteins, and pharmaceutical preparations of those proteins, gene expression constructs and cells and use in the treatment of various human conditions including cancer.

Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

Abstract: The present invention relates to methods of direct pulmonary delivery of polypeptides e.g. of domain antibodies, and to particular polypeptide compositions suitable for direct pulmonary delivery. The invention also relates to use of such compositions in medicine, e.g. for the treatment and diagnosis of lung disease, for example for treating Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Abstract: The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.

Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.

Abstract: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1? and/or IL-1?) to the receptor but do not inhibit binding of IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.

Abstract: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.

Abstract: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.

Abstract: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1? and/or IL-1?) and IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resist and dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.

Abstract: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.

Abstract: The present invention encompasses a naturally occurring, or synthetic polymer-linked polypeptide comprising one or more antibody domains.

Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.

Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.

Abstract: An enzymically active cell free extract or membrane fraction capable of catalysing the removal of nitrite from hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is provided. The cell free extract is produced by culturing a strain of Rhodococcus rhodochrous bacterium from nature. The strain designated 11Y has been deposited as NCIMB 40820. Methods of bioremediation using the enzymically active cell free extract so produced are also provided. Additionally there is provided a method for detecting the presence of RDX in a sample together with a biosensor for use in such a method. The nitrite produced in the enzyme catalysed reaction with RDX is detected, for example, colorimetrically, or alternatively a product of RDX degradation, such as formal behyde, is detected.